ACE inhibitor reduces cardiovascular events by 22%.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D015337:Multicenter Studies as Topic; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000401:mortality; D010091:Oximes / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017257:Ramipril / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D000806:Angiotensin-Converting Enzyme Inhibitors; D010091:Oximes; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors; D017257:Ramipril; D001241:Aspirin; C100917:sibrafiban